You are here

Venclexta

How AbbVie Could Make an Entry Into This Rapidly Growing Drug Market

How AbbVie Could Make an Entry Into This Rapidly Growing Drug Market

Motley Fool

breakthrough therapy

Flag link:

In next-gen BTK battle, AbbVie and J&J tout pivotal data backing Imbruvica as a combo treatment

In next-gen BTK battle, AbbVie and J&J tout pivotal data backing Imbruvica as a combo treatment

Endpoints

clinical trials

Flag link:

FDA grants full approval for Roche/AbbVie’s Venclexta in AML combination therapies

FDA grants full approval for Roche/AbbVie’s Venclexta in AML combination therapies

Pharmaforum

clinical trials

Flag link:

EHA: AbbVie, Roche cement Venclexta's place in AML with survival win

EHA: AbbVie, Roche cement Venclexta's place in AML with survival win

Fierce Pharma

Flag link:

AbbVie announces positive topline results from phase 3 trial of VENCLEXTA, Azacitidine combo in AML

AbbVie announces positive topline results from phase 3 trial of VENCLEXTA, Azacitidine combo in AML

Pharmaceutical Business Review

clinical trials

Flag link:

AbbVie, Roche's Venclexta nails confirmatory combo trial in AML after flopping earlier study

AbbVie, Roche's Venclexta nails confirmatory combo trial in AML after flopping earlier study

Fierce Pharma

clinical trials

Flag link:

AbbVie, Roche's Venclexta endangers AML approval with flopped confirmatory trial

AbbVie, Roche's Venclexta endangers AML approval with flopped confirmatory trial

Fierce Pharma

Flag link:

ASH: AbbVie, Roche pad their case for fixed-duration Venclexta use in CLL

ASH: AbbVie, Roche pad their case for fixed-duration Venclexta use in CLL

Fierce Pharma

Flag link:

Roche and Celgene set for battle in acute myelogenous leukaemia

Roche and Celgene set for battle in acute myelogenous leukaemia

EP Vantage

acute myeloid leukemia

Flag link:

5 Things You Need to Know From AbbVie's Q2 Earnings Results

5 Things You Need to Know From AbbVie's Q2 Earnings Results

Motley Fool

Flag link:

FDA lifts hold on AbbVie multiple myeloma study

FDA lifts hold on AbbVie multiple myeloma study

Biopharma Dive

clinical trials

Multiple Myeloma

Flag link:

AbbVie gets a green light to resume recruiting patients for one myeloma study — but Venclexta remains under a cloud

AbbVie gets a green light to resume recruiting patients for one myeloma study — but Venclexta remains under a cloud

Endpoints

Multiple Myeloma

clinical trials

Flag link:

ASCO Soundbites, vol. 3: Real-time approvals, Pfizer's second rodeo and 'the busiest ASCO ever'

ASCO Soundbites, vol. 3: Real-time approvals, Pfizer's second rodeo and 'the busiest ASCO ever'

Fierce Pharma

Flag link:

AbbVie, Roche snag another CLL nod, this time for Venclexta-Gazyva

AbbVie, Roche snag another CLL nod, this time for Venclexta-Gazyva

Fierce Pharma

small lymphocytic leukemia

Flag link:

2 Things Investors Are Missing About AbbVie

2 Things Investors Are Missing About AbbVie

Motley Fool

Flag link:

Genentech Submits sNDA For Venclexta and Gazyva Combo for Chronic Lymphocytic Leukemia

Genentech Submits sNDA For Venclexta and Gazyva Combo for Chronic Lymphocytic Leukemia

CP Wire

chronic lymphocytic leukemia

Flag link:

Genentech Submits sNDA For Venclexta and Gazyva Combo for Chronic Lymphocytic Leukemia

chronic lymphocytic leukemia

Flag link:

AbbVie’s cancer drug Venclexta blocks diabetes in mice by targeting beta cell ‘senescence’

AbbVie’s cancer drug Venclexta blocks diabetes in mice by targeting beta cell ‘senescence’

Fierce Biotech

type 1 diabetes

Flag link:

AbbVie, Roche aim to face down Pfizer with Venclexta’s move into AML arena

AbbVie, Roche aim to face down Pfizer with Venclexta’s move into AML arena

Fierce Pharma

Flag link:

FDA Approves Roche Subsidiary's Treatment for Acute Myeloid Leukemia

FDA Approves Roche Subsidiary's Treatment for Acute Myeloid Leukemia

Yahoo/Guru Focus

acute myeloid leukemia

Flag link:

Pages